Day: July 3, 2023

Tanić et al. Nature Biotechnology 2022

M Tanić, I. Moghul, S. Rodney, P. Dhami, H. Vaikkinen, J. Ambrose, J. Barrett, A. Feber, S. Beck. Performance comparison and in-silico harmonisation of commercial platforms for DNA methylome analysis by targeted bisulfite sequencing. Nature Biotechnology 2022. https://doi.org/10.1038/s41587-022-01336-9

Cavic et al. Oncology, 2022

Cavic M, Kovacevic T, Zaric B, Stojiljkovic D, Jovanovic Korda N, Rancic M, Jankovic R, Radosavljevic D, Stojanovic G, Spasic J. Lung Cancer in Serbia. Journal of Thoracic Oncology. 2022, 17(7): 867-872. https://doi.org/10.1016/j.jtho.2022.04.010

Jokic et al. Expert Review of Anticancer Therapy, 2021

Jokic V, Savic-Vujovic K, Spasic J, Marinkovic M, Stanic N, Radosavljevic D, Cavic M. Hematological parameters in EGFR-mutated advanced NSCLC patients treated with TKIs: predicting survival and toxicity. Expert Review of Anticancer Therapy. 2021. https://www.tandfonline.com/doi/full/10.1080/14737140.2021.1893694

Marinkovic M et al. Biomed Research International, 2022

Marinkovic M, Popovic M, Stojanovic-Rundic S, Nikolic M, Cavic M, Gavrilovic D, Teodorovic D, Mitrovic D, Mijatovic Teodorovic Lj. Comparison of Different Machine Learning Models in Prediction of Postirradiation Recurrence in Prostate Carcinoma Patients. Biomed Research International. 2022, 2022:7943609. https://doi.org/10.1155/2022/7943609.  

Jokic et al. Dose Response, 2022

Jokic V, Savic-Vujovic K, Spasic J, Bukumiric Z, Marinkovic M, Radosavljevic D, Cavic M. Evaluation of Clinical and Genetic Determinants of Treatment Outcome in EGFR Mutation Positive Advanced Lung Adenocarcinoma. Dose Response, 2022 Aug 4;20(3):15593258221117354. doi: 10.1177/15593258221117354.

Scroll to Top